Cure Ventures
- Company typePrivate
- Founded2021
- HeadquartersNewport Beach, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Cure Ventures firmographics
Firmographics- Name
- Cure Ventures
- Legal name
- Cure Ventures
- Website
- https://curevc.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Cure Ventures industry classification
Industry- Product category
- Life Sciences Venture Capital
- NAICS
- Open-End Investment Funds (525910)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Accelerators & Incubators (Investor-Operated) (FSANAAAM)
Keywords
Where Cure Ventures is headquartered
LocationHeadquarters
- HQ city
- Newport Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cure Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Venture capital fund management fees and carried interest: Cure Ventures Fund I, L.P. closed at a $350 million hard-cap. As a life sciences venture capital firm, Cure earns revenue primarily through management fees on committed/invested capital across its funds and carried interest on successful portfolio exits. Cure intends to co-lead subsequent Series A and B rounds of portfolio companies through to exits, supporting long-duration capital gains realization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Cure Ventures Fund I, L.P. — inaugural fund closed at $350 million hard-cap |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Cure Ventures product offering
Product offeringCore offering
Cure Ventures is a life sciences venture capital firm that funds and co-creates early-stage biotechnology companies around curative therapeutics. The firm manages its inaugural Cure Ventures Fund I, L.P., a $350 million fund closed at hard-cap in April 2023, and invests at Seed through Series B stages while embedding its scientific, technical, and financial operators (CTO, CFO, partners) as sweat-equity partners alongside portfolio founders. Capital is sourced from U.S. and international institutional LPs including public pensions, foundations, endowments, fund-of-funds, health systems, sovereign wealth funds, and family offices.
Product overview
Cure Ventures is a life-sciences venture capital firm (founded 2021) that operates a single platform of de novo biotech company formation rather than a packaged software product suite. Its core offering is the Cure Ventures Fund I, L.P. (a $350M venture fund closed April 2023) plus the hands-on scientific and operational support its partners provide to a growing portfolio of therapeutic startups. The portfolio companies that constitute Cure's commercial product surface include Aevum Therapeutics (neurodegeneration), Alessa Therapeutics (prostate cancer), Clasp Therapeutics (immuno-oncology TCEs), Crosslink Therapeutics (conditionally assembling cancer medicines), Kenai Therapeutics (dopamine neuron replacement for Parkinson's), Kobuk Therapeutics (precision biologics for autoimmune/inflammatory disease), Permeasis (intracellular biologics delivery platform), Recuro Health (virtual-first care delivery platform), Tasca Therapeutics (post-translational modification oncology platform), Tortugas Neuroscience (CNS small molecules), Triton Therapeutics (autoimmune/fibrotic disease), and XenImmune (antibody-enzyme fusion oncology). These portfolio companies collectively form Cure's investment and company-creation product offering.
Differentiator
Problem solved
Functional benefit
Products and services
- Cure Ventures Fund I, L.P. Inaugural $350 million life-sciences venture capital fund that finances Cure's de novo biotech company-formation strategy. Capital is committed by U.S. and international institutional limited partners and is deployed as Seed through Series B equity into early-stage therapeutic portfolio companies, with Cure operators embedded alongside founders. The fund is the sole flagship vehicle offered to LPs.
Quantifiable outcome
- $350 million inaugural fund closed at hard-cap on April 4, 2023
- +2 more outcomes
Companies that use Cure Ventures
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Cure Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Cure Ventures partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Eisai Co., Ltd.coreJapan-based Eisai is the source of in-licensed clinical-stage CNS programs that were de-risked into portfolio company Tortugas Neuroscience, targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. The licensing arrangement provides Tortugas/Cure-backed assets with existing clinical validation and established regulatory pathways.
- Jiangsu Hansoh Pharmaceutical GroupcoreChina-based Jiangsu Hansoh Pharmaceutical Group is the source of in-licensed clinical-stage CNS programs that became part of Tortugas Neuroscience's pipeline alongside assets licensed from Eisai. Together, the two Asian pharma partners supplied four phase 2-stage drug assets in-licensed by the Cure-backed portfolio company.
- SightsaversminorFeatured community partnership on the Cure Ventures website; Sightsavers is a nonprofit eliminating avoidable blindness and supporting people with disabilities in over 30 countries across Africa and Asia. Cure supports the organization through philanthropic engagement outside of core biotech investing.
- MiracleFeetminorFeatured community partnership on the Cure Ventures website; MiracleFeet is a nonprofit treating clubfoot in low-income countries (79,000+ children across 30+ countries as of March 2023). Partnership was initiated after a Cure employee heard BBC coverage in December 2022, with CEO Daphne de Souza Lima Sorensen publicly endorsing Cure's mission alignment.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Cure Ventures competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Early-stage life sciences venture firm that builds biotech companies from inception, paralleling Cure's de novo formation model. Both back Seed/Series A with embedded operating support and have Boston presence.
- Third Rock Ventures: Biotech company-formation firm that conceives, builds, and operates new companies. Cure co-founder Lou Tartaglia was previously a Partner at Third Rock, and Senior Associate Kayarash Karimian joined from Third Rock — direct lineage and a highly comparable operating model.
- 5AM Venture: Early-stage life sciences VC with a company-creation focus. Lou Tartaglia previously led 5AM's 4:59 program before co-founding Cure, and both firms target de novo biotech formation around breakthrough science.
- The Column Group: Life-sciences-dedicated venture firm co-led the $106M Tortugas Neuroscience round with Cure. Both firms are science-led, fund early-stage biotech, and co-invest in CNS and oncology programs.
- ARCH Venture Partners: Long-tenured biotech creation firm that partners with academic founders to launch therapeutic companies. Associate Weihan Liu interned at ARCH, and the firm competes head-to-head with Cure for early-stage biotech deal flow.
- SV Health Investors: Healthcare-focused VC with a strong biotech-creation practice. Targets similar Seed/Series A biotech investments, often with operator-embedded models, making it a direct peer in life-sciences venture.
Broad incumbents
- Omega Funds: Healthcare-dedicated investment firm where co-founder Richard Lim was previously Managing Member/President, and where investment team member Annie Mitsak also worked. Comparable in life-sciences mandate but operates as a broader healthcare investor.
- MVM Life Science Partners: Global healthcare VC where Richard Lim was previously a Managing Director. Invests across stages of biotech and medtech; comparable investor base and life-sciences focus.
- Polaris Partners: Multi-stage venture firm with a life-sciences practice. Co-founder David Fallace was previously an Advisor at Polaris. Overlaps with Cure on early-stage biotech and digital health (Recuro Health parallels Polaris' health-tech portfolio).
- New Enterprise Associates (NEA): Large multi-stage VC with a substantial healthcare/biotech practice. Invests across Seed through growth, including life-sciences company formation, and competes broadly with Cure for biotech deal flow.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Cure Ventures social profiles
Digital presenceCure Ventures compliance and trust
Trust signalCompliance2 records
Cure Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cure Ventures leadership team
Management profileNumber of profiles
Profiles11 records
Cure Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cure Ventures M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cure Ventures
What does Cure Ventures do?
Cure Ventures is a life sciences venture capital firm that funds and co-creates early-stage biotechnology companies around curative therapeutics. The firm manages its inaugural Cure Ventures Fund I, L.P., a $350 million fund closed at hard-cap in April 2023, and invests at Seed through Series B stages while embedding its scientific, technical, and financial operators (CTO, CFO, partners) as sweat-equity partners alongside portfolio founders. Capital is sourced from U.S. and international institutional LPs including public pensions, foundations, endowments, fund-of-funds, health systems, sovereign wealth funds, and family offices.
Is Cure Ventures a public or private company?
Cure Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cure Ventures founded?
Cure Ventures was founded in 2021. It employs 1 to 10 people.
Where is Cure Ventures based?
Cure Ventures is headquartered in Newport Beach, United States, in the North America region.
How does Cure Ventures make money?
One revenue line is on record: venture capital fund management fees and carried interest.
Who are Cure Ventures's main competitors?
Direct peers on record are Atlas Venture, Third Rock Ventures, 5AM Venture, The Column Group, ARCH Venture Partners and SV Health Investors. Broad incumbents are Omega Funds, MVM Life Science Partners, Polaris Partners and New Enterprise Associates (NEA).
Does Cure Ventures have an API?
No public API is recorded for Cure Ventures.
What industry is Cure Ventures in?
Cure Ventures's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAM, Accelerators & Incubators (Investor-Operated). Its NAICS code is 525910 and its SIC code is 6282.